Leone Patterson compensation by year
Zymeworks Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $161,667 |
| Bonus | $50,000 |
| Stock awards | $0 |
| Option awards | $2,590,403 |
| Non-equity incentive | $99,849 |
| Pension and deferred compensation | $0 |
| All other | $6,063 |
| Total | $2,907,982 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zymeworks Inc. DEF 14A filed November 10, 2025, accession 0001193125-25-274338, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 360,000 | — | $11.73 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Zymeworks Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2024 proxy (filed November 10, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-06 | Grant or award | — | 459 | $10.55 | 459 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Zymeworks discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $485,000 | $0 | — | — |
| Change in control and involuntary termination | $727,500 | $1,047,600 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Zymeworks Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
Zymeworks’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kenneth Galbraith | Chief Executive Officer, President and Chair of Board of Directors | $5,253,616 |
| Leone Patterson · this page | Executive Vice President, Chief Business Officer and Chief Financial Officer | $2,907,982 |
| Paul Moore | Chief Scientific Officer | $1,986,803 |
The full Zymeworks compensation record
free company briefThis page is one person within Zymeworks's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Zymeworks's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zymeworks's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat